Peptide syringe programs ration free equipment as peptide users surge

Peptide syringe programs in Australia are running short of free equipment. Directions Health Services, a Canberra charity funded by the ACT government, said in an ABC News report on 28 October 2026 that it has limited some of the injecting supplies it hands out, because more people want them to inject peptides. The charity says social media influencers are steering peptide users to harm minimisation services. It wants to keep stock for people who inject drugs such as heroin or amphetamine. No national count was published.

What Directions Health Services reported in Canberra

Directions Health Services runs a needle and syringe program, one of the services built to stem blood borne viruses such as HIV. Acting chief executive Stephanie Stephens told the ABC that for a decade its clients mostly sought equipment for heroin or amphetamine. Stephens said the service has seen an enormous surge in people collecting sharps and needles to use peptides, and that the rise continues month by month. Staff can track this because they ask each client what they last injected, and clients may decline to answer. The charity said it has restricted some injecting equipment so it can keep helping more marginalised drug users. The report does not say which items are limited, or by how much.

Supply is the second pressure on peptide syringe programs. Tammy Waters, who leads the program, said the rise in peptide use is straining needle and syringe programs across the country, and that her supplier cannot deliver as much stock as she orders. The service has also seen the cost of safely removing and disposing of clinical waste go up. Stephens said many people buy unregulated peptides through social media, and that those who can afford it should also pay for their own syringes. That, she said, would leave free stock for marginalised groups, including people who inject drugs. The ABC report does not give the charity's budget, its stock levels or the size of the cost increase.

Why unregulated peptides strain harm minimisation

Peptides are short chains of amino acids, and the ABC notes that the Therapeutic Goods Administration has approved some peptide medicines while many other products are unregulated. The harm is already visible in hospitals. NSW hospital data show how fast the problem grew: peptide related hospitalisations rose from five in July 2025 to more than 200 in September 2026, according to a Medical Xpress article. That article also says new injectors often do not think of themselves as drug injectors, so they may not look for safe injecting advice. Unregulated peptides arrive with no leaflet and no health professional, and buyers often learn from forums, influencers or friends.

NSW hospital data show how fast the problem grew: peptide related hospitalisations rose from five in July 2025 to more than 200 in September 2026, according to a Medical Xpress article.

The same pattern shows up in our own reporting, where NSW emergency visits tied to unapproved peptides reached 217 a month, with retatrutide named most often. NSW Health officials say none of those products is approved in Australia. Dr Kerry Chant, the state's Chief Health Officer, has warned that a professional looking website, a label, reviews or an influencer endorsement does not prove what is inside a vial. For harm minimisation workers the problem is practical. A clean syringe lowers one risk, but it cannot tell a client whether the contents are real, correctly made or safe. That uncertainty belongs to the gray market, not to the clinics trying to cope with its customers.

Needle and syringe programs under pressure across Australia

Canberra is not alone among peptide syringe programs. In June the ABC reported that Peer Based Harm Reduction, which runs the largest needle and syringe exchange in Western Australia, said the number of people collecting equipment for synthetic peptides had doubled in three years. A Mandurah service said it had seen an astronomical rise in needles linked to steroids and peptides since 2020, though still a small share of its work. In August, Mary Harrod of the Needle Users and AIDS Association said her group was contracted to give out 500,000 needles and syringes and was now near two million. She said it could not keep up with that demand.

Harrod also warned that the strain could leave at risk drug users without safe equipment, and that some might share syringes. She said rural vending machines, which handle much of the distribution, were being emptied within an hour or two of being filled. Her group, she said, would have to let go of two or three staff to keep pace. These are statements from service leaders, not audited figures, and each service counts differently. Even so, the reports from Western Australia, New South Wales and the ACT point the same way: demand on peptide syringe programs is rising faster than contracted budgets and supplier deliveries.

Who is affected and what is unknown

For patients who use peptides, the main change is that free syringes at harm minimisation charities may be harder to get, and the charity itself asks those who can pay to cover their own. For prescribers, the report is a reminder that approved peptide medicines go through a doctor, while the products behind the surge do not. Pharmacies sit outside this story, since the supplies at issue come from publicly funded services. Payers, here the ACT government and other funders, are being pressed by rising demand and waste costs. For sellers of unapproved products, the charity's concern is that influencers send buyers to free equipment.

Much is still unknown. The ABC report gives no figure for how many peptide clients the Canberra service sees, no detail on the limits it set, and no response from the ACT government. It is also unclear whether other services will follow. Social media sits at the center of the story, and our coverage of TikTok peptide searches going blank shows how unsettled that channel is. A survey on GLP 1 misinformation from TikTok found clinicians already correct patients weekly. The charity's own advice that people who can pay should buy their own supplies shows how tight its stock has become. This is research reporting, not medical advice, and anyone with a prescription question should ask a registered prescriber.

Conclusion

Peptide syringe programs now carry a cost that no budget line planned for. Directions Health Services has limited some equipment, other services report similar strain, and suppliers cannot fill orders. The report offers no national figure and no funder response yet. Watch for ACT government comment, any similar limits elsewhere, and whether unapproved peptides stay a gray market problem for harm minimisation staff.